Rel­ma­da’s ma­jor de­pres­sion drug shows PhI­II promise in a fresh batch of pa­tients

Rel­ma­da Ther­a­peu­tics’ once-dai­ly REL-1017 has shown pos­i­tive da­ta in ma­jor de­pres­sive dis­or­der (MDD) from a reg­is­tra­tional Phase III tri­al, a year af­ter an un­ex­pect­ed late …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER